Browse PROS1

Summary
SymbolPROS1
Nameprotein S (alpha)
Aliases PROS; PS21; PS22; PS23; PS24; PS25; THPH5; THPH6; protein Sa; vitamin K-dependent plasma protein S; Vitamin ......
Chromosomal Location3q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00008 EGF-like domain
PF07645 Calcium-binding EGF domain
PF00594 Vitamin K-dependent carboxylation/gamma-carboxyglutamic (GLA) domain
PF00054 Laminin G domain
PF02210 Laminin G domain
Function

Anticoagulant plasma protein; it is a cofactor to activated protein C in the degradation of coagulation factors Va and VIIIa. It helps to prevent coagulation and stimulating fibrinolysis.

> Gene Ontology
 
Biological Process GO:0002526 acute inflammatory response
GO:0002576 platelet degranulation
GO:0002673 regulation of acute inflammatory response
GO:0002697 regulation of immune effector process
GO:0002920 regulation of humoral immune response
GO:0006465 signal peptide processing
GO:0006887 exocytosis
GO:0006888 ER to Golgi vesicle-mediated transport
GO:0006956 complement activation
GO:0006959 humoral immune response
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0010466 negative regulation of peptidase activity
GO:0010951 negative regulation of endopeptidase activity
GO:0016485 protein processing
GO:0017187 peptidyl-glutamic acid carboxylation
GO:0018200 peptidyl-glutamic acid modification
GO:0018214 protein carboxylation
GO:0030193 regulation of blood coagulation
GO:0030195 negative regulation of blood coagulation
GO:0030449 regulation of complement activation
GO:0032102 negative regulation of response to external stimulus
GO:0042730 fibrinolysis
GO:0045055 regulated exocytosis
GO:0045861 negative regulation of proteolysis
GO:0048193 Golgi vesicle transport
GO:0050727 regulation of inflammatory response
GO:0050817 coagulation
GO:0050818 regulation of coagulation
GO:0050819 negative regulation of coagulation
GO:0050878 regulation of body fluid levels
GO:0050900 leukocyte migration
GO:0051346 negative regulation of hydrolase activity
GO:0051604 protein maturation
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0061041 regulation of wound healing
GO:0061045 negative regulation of wound healing
GO:0070613 regulation of protein processing
GO:0072376 protein activation cascade
GO:1900046 regulation of hemostasis
GO:1900047 negative regulation of hemostasis
GO:1903034 regulation of response to wounding
GO:1903035 negative regulation of response to wounding
GO:1903317 regulation of protein maturation
GO:2000257 regulation of protein activation cascade
Molecular Function GO:0004857 enzyme inhibitor activity
GO:0004866 endopeptidase inhibitor activity
GO:0030414 peptidase inhibitor activity
GO:0061134 peptidase regulator activity
GO:0061135 endopeptidase regulator activity
Cellular Component GO:0005796 Golgi lumen
GO:0030141 secretory granule
GO:0031091 platelet alpha granule
GO:0031093 platelet alpha granule lumen
GO:0031983 vesicle lumen
GO:0034774 secretory granule lumen
GO:0060205 cytoplasmic membrane-bounded vesicle lumen
GO:0072562 blood microparticle
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG hsa04610 Complement and coagulation cascades
Reactome R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-140875: Common Pathway of Fibrin Clot Formation
R-HSA-166658: Complement cascade
R-HSA-140877: Formation of Fibrin Clot (Clotting Cascade)
R-HSA-163841: Gamma carboxylation, hypusine formation and arylsulfatase activation
R-HSA-159740: Gamma-carboxylation of protein precursors
R-HSA-159854: Gamma-carboxylation, transport, and amino-terminal cleavage of proteins
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-392499: Metabolism of proteins
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-114608: Platelet degranulation
R-HSA-597592: Post-translational protein modification
R-HSA-977606: Regulation of Complement cascade
R-HSA-159782: Removal of aminoterminal propeptides from gamma-carboxylated proteins
R-HSA-76005: Response to elevated platelet cytosolic Ca2+
R-HSA-159763: Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus
Summary
SymbolPROS1
Nameprotein S (alpha)
Aliases PROS; PS21; PS22; PS23; PS24; PS25; THPH5; THPH6; protein Sa; vitamin K-dependent plasma protein S; Vitamin ......
Chromosomal Location3q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PROS1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PROS1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29708510MelanomaInhibit immunityTumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response. We demonstrate that tumor-secreted protein S (Pros1), a Mer/Tyro3 ligand, decreased macrophage M1 cytokine expression in vitro and in vivo. Mice bearing Pros1-deficient tumors showed increased innate and adaptive immune infiltration, as well as increased median survival.
Summary
SymbolPROS1
Nameprotein S (alpha)
Aliases PROS; PS21; PS22; PS23; PS24; PS25; THPH5; THPH6; protein Sa; vitamin K-dependent plasma protein S; Vitamin ......
Chromosomal Location3q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PROS1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPROS1
Nameprotein S (alpha)
Aliases PROS; PS21; PS22; PS23; PS24; PS25; THPH5; THPH6; protein Sa; vitamin K-dependent plasma protein S; Vitamin ......
Chromosomal Location3q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PROS1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0980.824
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.5170.834
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.5610.727
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2840.485
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3360.821
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2180.907
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0470.936
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2450.896
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2620.905
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0560.976
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0380.99
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4420.00306
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PROS1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.49.6-2.21
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.411.9-4.50.713
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.67.4-4.80.565
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 2213015.4-15.40.131
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPROS1
Nameprotein S (alpha)
Aliases PROS; PS21; PS22; PS23; PS24; PS25; THPH5; THPH6; protein Sa; vitamin K-dependent plasma protein S; Vitamin ......
Chromosomal Location3q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PROS1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPROS1
Nameprotein S (alpha)
Aliases PROS; PS21; PS22; PS23; PS24; PS25; THPH5; THPH6; protein Sa; vitamin K-dependent plasma protein S; Vitamin ......
Chromosomal Location3q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PROS1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PROS1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPROS1
Nameprotein S (alpha)
Aliases PROS; PS21; PS22; PS23; PS24; PS25; THPH5; THPH6; protein Sa; vitamin K-dependent plasma protein S; Vitamin ......
Chromosomal Location3q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PROS1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPROS1
Nameprotein S (alpha)
Aliases PROS; PS21; PS22; PS23; PS24; PS25; THPH5; THPH6; protein Sa; vitamin K-dependent plasma protein S; Vitamin ......
Chromosomal Location3q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PROS1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPROS1
Nameprotein S (alpha)
Aliases PROS; PS21; PS22; PS23; PS24; PS25; THPH5; THPH6; protein Sa; vitamin K-dependent plasma protein S; Vitamin ......
Chromosomal Location3q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PROS1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPROS1
Nameprotein S (alpha)
Aliases PROS; PS21; PS22; PS23; PS24; PS25; THPH5; THPH6; protein Sa; vitamin K-dependent plasma protein S; Vitamin ......
Chromosomal Location3q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PROS1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PROS1.
ID Name Drug Type Targets #Targets
DB00055Drotrecogin alfaBiotechCP, F2, F5, F8, GGCX, PF4, PROCR, PROS1, SERPINA5, SERPINB6, SERPI ......12
DB00170MenadioneSmall MoleculeBGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC ......13
DB00464Sodium Tetradecyl SulfateSmall MoleculePROC, PROS12
DB09332KappadioneSmall MoleculeF10, F2, F7, F9, GGCX, PROC, PROS17